TEL AVIV, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, February 19, 2019, to discuss financial results for the three and twelve months ended December 31, 2018, and provide a corporate update.
|Conference Call & Webcast:|
|Tuesday, February 19 @ 8:00am Eastern Time|
|Within the US:||877-451-6152|
|Outside the US:||201-389-0879|
|Israel:||1 809 406 247|
|Replays, Available through March 5th:|
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Chief Financial Officer
LifeSci Advisors, LLC